639 related articles for article (PubMed ID: 22126246)
21. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
22. Development of curcumin as an epigenetic agent.
Fu S; Kurzrock R
Cancer; 2010 Oct; 116(20):4670-6. PubMed ID: 20597137
[TBL] [Abstract][Full Text] [Related]
23. Histone post-translational modification: from discovery to the clinic.
Thomas NR
IDrugs; 2006 Jun; 9(6):398-401. PubMed ID: 16752306
[No Abstract] [Full Text] [Related]
24. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
25. Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.
Bayo J; Dalvi MP; Martinez ED
Future Med Chem; 2015; 7(16):2243-61. PubMed ID: 26510529
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
28. Abnormal epigenetic modifications in peripheral blood mononuclear cells from patients with alopecia areata.
Zhao M; Liang G; Wu X; Wang S; Zhang P; Su Y; Yin H; Tan Y; Zhang J; Lu Q
Br J Dermatol; 2012 Feb; 166(2):226-73. PubMed ID: 21936853
[TBL] [Abstract][Full Text] [Related]
29. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
31. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
32. Chromatin-remodelling mechanisms in cancer.
Lafon-Hughes L; Di Tomaso MV; Méndez-Acuña L; Martínez-López W
Mutat Res; 2008; 658(3):191-214. PubMed ID: 18403253
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic modulators as therapeutic targets in prostate cancer.
Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
35. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
Fischer A
Neuropharmacology; 2014 May; 80():95-102. PubMed ID: 24486385
[TBL] [Abstract][Full Text] [Related]
36. SnapShot: Histone-modifying enzymes.
Kouzarides T
Cell; 2007 Nov; 131(4):822. PubMed ID: 18022374
[No Abstract] [Full Text] [Related]
37. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
38. Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells.
Li CT; Hsiao YM; Wu TC; Lin YW; Yeh KT; Ko JL
J Cell Biochem; 2011 Oct; 112(10):3044-53. PubMed ID: 21678477
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic cancer therapy: rationales, targets and drugs.
Rius M; Lyko F
Oncogene; 2012 Sep; 31(39):4257-65. PubMed ID: 22179827
[TBL] [Abstract][Full Text] [Related]
40. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
